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Abstract: Certain viruses have the ability to subvert the mammalian immune response, including
interference in the chemokine system. Poxviruses produce the chemokine binding protein vCCI
(viral CC chemokine inhibitor; also called 35K), which tightly binds to CC chemokines. To facilitate
the study of vCCI, we first provide a protocol to produce folded vCCI from Escherichia coli (E. coli.)
It is shown here that vCCI binds with unusually high affinity to viral Macrophage Inflammatory
Protein-II (vMIP-II), a chemokine analog produced by the virus, human herpesvirus 8 (HHV-8).
Fluorescence anisotropy was used to investigate the vCCI:vMIP-II complex and shows that vCCI
binds to vMIP-II with a higher affinity than most other chemokines, having a Kd of 0.06 ± 0.006 nM.
Nuclear magnetic resonance (NMR) chemical shift perturbation experiments indicate that key amino
acids used for binding in the complex are similar to those found in previous work. Molecular
dynamics were then used to compare the vCCI:vMIP-II complex with the known vCCI:Macrophage
Inflammatory Protein-1β/CC-Chemokine Ligand 4 (MIP-1β/CCL4) complex. The simulations show
key interactions, such as those between E143 and D75 in vCCI/35K and R18 in vMIP-II. Further, in a
comparison of 1 µs molecular dynamics (MD) trajectories, vMIP-II shows more overall surface binding
to vCCI than does the chemokine MIP-1β. vMIP-II maintains unique contacts at its N-terminus to
vCCI that are not made by MIP-1β, and vMIP-II also makes more contacts with the vCCI flexible acidic
loop (located between the second and third beta strands) than does MIP-1β. These studies provide
evidence for the basis of the tight vCCI:vMIP-II interaction while elucidating the vCCI:MIP-1β
interaction, and allow insight into the structure of proteins that are capable of broadly subverting the
mammalian immune system.
Keywords: chemokine binding protein; chemokine analog; anti-inflammation; 35K; vCCI; vMIP-II;
MIP-1β/CCL4; molecular dynamics

1. Introduction
Protein–protein interactions are critical for many aspects of biological and immunological function.
Of particular interest are virally-encoded proteins that undermine the immune system, often by
having the ability to promiscuously bind many targets, and therefore, help the virus evade immune
surveillance. One such system targeted by viruses is the chemokine system, in which virally encoded
proteins disrupt the chemokine receptor/ligand interaction [1]. Chemokines (chemotactic cytokines)
are a class of small secreted proteins that mediate immune cell chemotaxis as part of the inflammatory
response. There are about 18 human chemokine receptors that are activated upon binding to their
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cognate chemokine ligand [2]. About 50 chemokine ligands are known, spanning 4 sub-families.
The two major subfamilies are CC chemokines (named for the adjacent Cys near the N-terminus of the
protein) and CXC chemokines (named for having an intervening amino acid between the conserved
N-terminal Cys). In general, CC chemokines (named numerically as CCL1; chemokine ligand 1,
etc.) bind to and activate cognate receptors on the surfaces of monocytes, macrophages and T-cells,
and these receptors are numerically named as CC receptors (e.g., CCR1, CCR2). CXC chemokines tend
to have cognate receptors on the surface of neutrophils [2], with receptors such as CXCR1. Chemokines
can sometimes bind multiple receptors, and receptors often have more than one cognate ligand,
although CC chemokines are restricted to CC chemokine receptors, and CXC chemokines have their
own CXC receptors.
Because of the central nature of the chemokine system in activating and localizing immune
cells, subversion of the process may be useful to a virus. Several types of chemokine-binding
proteins (CKBPs) have been identified (reviewed in [3]), including those that bind chemokines from
multiple subfamilies, such as Myxoma-T7 (M-T7) from myxoma [4], M3 from γ-herpesvirus-68 [5–8],
and the poxvirus-encoded smallpox virus-encoded chemokine receptor (SECRET) domain [9].
These proteins have gained interest as inflammation inhibitors, due to their ability to bind to
pro-inflammatory proteins.
One of the most potent inhibitors of chemokine action is the poxvirus-encoded protein vCCI
(viral CC chemokine inhibitor; also called 35K). This approximately 240 amino acid protein binds
80 CC-chemokines across several species, about 20 of which have nanomolar affinity to this
inhibitor [10,11]. The protein sequence across several poxviruses shows high identity, and the
structures from cowpox [12], rabbitpox [13], and mousepox [14] reveal a beta sandwich with a binding
face containing several key negatively charged amino acids, as well as a long acidic loop between beta
strands 2 and 3. We have carried out structural studies of vCCI in complex with MIP-1β (also called
CCL4 [13]), which revealed details of the interaction between vCCI and the chemokine, including
several close contacts that are critical for binding. Mutagenesis of vCCI/35K by others, in vitro and
in vivo, has confirmed the importance of several of the residues suggested by the structure, including
E143 and the acidic loop [14,15]. Mutagenesis studies on the chemokines themselves have also been
carried out by us and others and indicate that several evolutionarily conserved, positively charged
residues are important for binding to vCCI/35K [11,16,17]. In our work, with a variety of eotaxin
mutants (CCL11 [11]), we showed that eotaxin’s binding to vCCI was dependent on the presence of
several basic residues in the chemokine.
Viruses have also evolved the ability to interfere with the chemokine system by producing
chemokine homologs, small proteins that mimic the chemokine’s ability to bind a chemokine receptor,
thus blocking the native chemokine. Herpesvirus HHV-8 encodes several such chemokine analogs;
of particular interest is the protein vMIP-II (virally encoded macrophage inflammatory protein-II),
which has about 40% identity with the human CC chemokine MIP-1β, and has been shown to bind
and antagonize several CC chemokine receptors (CCR1, CCR2, CCR5, though it can agonize CCR3
and CCR8), as well as at least one CXC receptor (CXCR4) [18–20]. This range of receptor binding is
much greater than a typical chemokine. We have previously studied vMIP-II to elucidate its ability to
bind glycosaminoglycans, and have shown that, in solution, it is a soluble monomer with a fold similar
to that of MIP-1β [21,22]. Due to its nanomolar affinity to, and broad ability to bind to chemokine
receptors [18,22], vMIP-II has engendered interest as an anti-inflammatory agent, with some success in
rat studies involving ischemic stroke [23], spinal cord injury [24], and kidney transplant rejection [25].
vCCI and vMIP-II are therefore complementary proteins, the former having evolved to bind a
large variety of CC chemokines, and the latter having evolved to be a prototypical chemokine ligand
with the ability to bind many receptors. While we have studied these proteins in complex with their
natural ligands [11,13,22,26], we developed the hypothesis that a significant amount of insight could
be obtained by determining whether a tight complex could be formed by these proteins. In other
words, we set out to study the complex between an “ideal” chemokine binding protein (vCCI) and an
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“ideal” chemokine homolog (vMIP-II). Due to the broad action of these proteins, an understanding of
these powerful viral tools may be helpful in designing strategies to manipulate or control immune
responses, and could be applicable to fields ranging from autoimmunity to traumatic brain injury.
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of vCCI to vMIP-II is higher than that between vCCI and natural chemokines [11,18] and suggest
2. Results
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pastoris yeast expression (Figure 1A and S1). Further, this protein forms a complex upon addition of
upon addition
of chemokine analog vMIP-II (Figure 1B), showing its functionality.
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Figure 1. (A) 1H-15N heteronuclear single quantum coherence (HSQC) spectrum of unbound

15

N-

Figure 1. (A) 1 H-15 N heteronuclear single quantum coherence (HSQC) spectrum of unbound
labeled vCCI in 100 mM NaCl, 20 mM NaOP (sodium phosphate) pH 7.0, measured at 37 °C; (B)
15 N-labeled vCCI in 100 mM NaCl, 20 mM NaOP (sodium phosphate) pH 7.0, measured at 37 ◦ C;
Overlay of the 1H-15N HSQC spectra of free 15N-labeled viral CC chemokine inhibitor (vCCI) (black)
1 H-15 N HSQC spectra of free 15 N-labeled viral CC chemokine inhibitor (vCCI)
(B) Overlay
the14N
and 15N of
vCCI:
vMIP-II (red) with a ratio of 1:3, measured under the same conditions as in (A). The
15
14 N vMIP-II (red) with a ratio of 1:3, measured under the same conditions as in
(black)concentration
and N vCCI:
of vCCI
was 50–60 μM.
(A). The concentration of vCCI was 50–60 µM.
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2.2. vCCI:vMIP-II
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a
To determine
amino
acids
that are
in the vCCI:vMIP-II
complex, a complex,
comparison
comparison
chemical
shift
changesthe
between
thebound
free and
bound
of both vCCI/35K
and vMIPof chemical of
shift
changes
between
free and
forms
offorms
both vCCI/35K
and vMIP-II
was
15N HSQC spectra in the free and bound form using15
15N labeled
II
was
carried
out.
In
the
case
of
vCCI,
15
carried out. In the case of vCCI, N HSQC spectra in the free and bound form using N labeled
vCCI
vCCI (with
(with non-isotopically
non-isotopically labeled
labeled vMIP-II)
vMIP-II) were
were measured
measured and
and compared,
compared, to
to determine
determine the
the level
level
of
peak
movement
upon
complex
formation.
(Assignments
of
the
unbound
vCCI
were
obtained
from
of peak movement upon complex formation. (Assignments of the unbound vCCI were obtained
[27]
Magnetic
Resonance
Bank (BMRB)
databank
6809.) 6809.)
Chemical
shift changes
in the
fromand
[27]Biological
and Biological
Magnetic
Resonance
Bank (BMRB)
databank
Chemical
shift changes
15N vMIP-II
HSQC
spectrum
upon
binding
non-isotopically
labeled
vCCI/35K
were
also
determined.
15
in the N vMIP-II HSQC spectrum upon binding non-isotopically labeled vCCI/35K were also
In
cases where
assignment ofassignment
the peak inofthe
spectrum
wasspectrum
not possible,
determined.
Inunambiguous
cases where unambiguous
thebound
peak in
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Figure 3. Changes in chemical shift upon complex formation. (A) Changes in chemical shift in vCCI

Figure 3. Changes in chemical shift upon complex formation. (A) Changes in chemical shift in vCCI
upon binding to vMIP-II. Arrows represent beta strands while spiral lines represent alpha helices. See
upon binding to vMIP-II. Arrows represent beta strands while spiral lines represent alpha helices.
Table 1 for definitions of “0”, “1”, “2”, “3”; (B) Structure showing changes in vCCI (Protein Data Bank
See Table
1 for definitions
of vMIP-II.
“0”, “1”,Green
“2”, “3”;
(B) Structure
showing
changes
vCCI (Protein
Data
code 2FFK
upon binding
indicates
greater than
average,
up to 1instandard
deviation
Bankaway
code 2FFK
upon
binding
vMIP-II.
Green
indicates
greater
than
average,
up
to
1
standard
deviation
from the average; yellow indicates over 1 standard deviation away from the average; red
awayindicates
from thebelow
average;
yellow indicates
1 standard
away from(C)
theChanges
average;inred
indicates
one standard
deviationover
or the
peak had deviation
not been discernable;
chemical
below
one
standard
deviation
or
the
peak
had
not
been
discernable;
(C)
Changes
in
chemical
shift
shift in vMIP-II upon binding to vCCI. Secondary structure is shown by arrows and spiral lines, as in
in vMIP-II
to vCCI.ofSecondary
structure
shown by
arrowsthose
and changes
spiral lines,
as in (A).
(A). Seeupon
Tablebinding
1 for definitions
“0”, “1”, “2”,
“3”; (D)isStructure
showing
in vMIP-II
upon 1binding
vCCI (Protein
1VMP).
Green showing
indicates those
greaterchanges
than average,
up toupon
1
See Table
for definitions
of “0”,Data
“1”,Bank
“2”, code
“3”; (D)
Structure
in vMIP-II
standard
away Bank
from the
average;
yellow
indicates
over
1 standard
the
binding
vCCIdeviation
(Protein Data
code
1VMP).
Green
indicates
greater
thandeviation
average, away
up tofrom
1 standard
average;
blue
indicates
below one
standard
deviation
the peakdeviation
had not been
All
deviation
away
from
the average;
yellow
indicates
over 1orstandard
awaydiscernable.
from the average;
prepared deviation
by using or
UCSF
Resource
for Biocomputing,
blue structure
indicatesfigures
below were
one standard
the Chimera
peak had(UCSF
not been
discernable.
All structure
Visualization,
and Informatics,
San Francisco,
CA,
USA) [28].
figures
were prepared
by using UCSF
Chimera
(UCSF
Resource for Biocomputing, Visualization,
and Informatics, San Francisco, CA, USA) [28].
Table 1. Definitions of the chemical shift perturbation categories in Figure 3.

Chemical Shift
Table 1. Definitions
of the chemical shift perturbation
categories
Figure Chemical
3.
Definition
vCCI Chemical
Shift invMIP-II
Shift
Perturbation
No confirmable change
No peaks visible
NovMIP-II
peaks visible
Chemical0Shift
Chemical
vCCI
Shift
1
Less than Definition
or equal to average
ΔδobsChemical
≤ 0.045
Δδobs ≤ 0.100
Perturbation
Shift
Greater than average, up to one
0 2
No confirmable
peaks
visible
visible
standard
deviationchange
above
0.045No
< Δδ
obs ≤ 0.086
0.100 <No
Δδpeaks
obs ≤ 0.178
1
Less than average
or equal to average
∆δobs ≤ 0.045
∆δobs ≤ 0.100
Greater than one standard
Greater than average, up to one
3
Δδobs ≥ 0.178
Δδobs ≥ 0.086
deviation above average

2

standard deviation above

0.045 < ∆δobs ≤ 0.086

0.100 < ∆δobs ≤ 0.178

Δδobs: the difference in chemical
shift between bound and free form of 15N-labeled complexes, as
average
defined in Methods.

Greater than one standard
3
∆δobs ≥ 0.086
∆δobs ≥ 0.178
deviation above average
As shown in Figure 3A, the areas of greatest chemical shift change for vCCI/35K upon binding to
∆δobs: the
chemical
between
bound
free
formand
of 15
N-labeled
complexes,
as observed
defined
vMIP-II
aredifference
located ininthe
region shift
of amino
acids
in theand
80’s,
140’s,
190’s,
with changes
also
in Methods.
in the 30’s, 170’s–180’s and 220’s. These areas are shown on the structure of vCCI/35K (shown without
vMIP-II) in Figure 3B, and indicate a binding surface similar to those shown previously [11,13,14,27],
As shown of
in negative
Figure 3A,
the areas
ofE143,
greatest
chemical
shift
for charged
vCCI/35K
binding
comprised
charges
(D141,
as well
as likely
thechange
negatively
loopupon
in the
52–77 to

vMIP-II are located in the region of amino acids in the 80’s, 140’s, and 190’s, with changes also observed
in the 30’s, 170’s–180’s and 220’s. These areas are shown on the structure of vCCI/35K (shown without
vMIP-II) in Figure 3B, and indicate a binding surface similar to those shown previously [11,13,14,27],
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comprised of negative charges (D141, E143, as well as likely the negatively charged loop in the 52–77
region that is not clearly assignable, likely due to flexibility) as well as interaction in the early 80’s
region. Figure
Int. J. Mol.3C
Sci. indicates
2017, 18, 1778that vMIP-II interacts with vCCI/35K using residues from its N-loop
6 of 18 region
(residues 12–19), and with the second beta strand in the 30’s region, as well as with residues in the
region
that is3D
notshows
clearly assignable,
likelypresumed
due to flexibility)
as well asregions
interaction
in the early 80’s region.
early 50’s.
Figure
vMIP-II with
interacting
highlighted.
Figure 3C indicates that vMIP-II interacts with vCCI/35K using residues from its N-loop region

(residues
12–19), and
with the second
beta strand in the 30’s region, as well as with residues in the early
2.4. Molecular
Dynamics
Simulations
on vCCI:vMIP-II
50’s. Figure 3D shows vMIP-II with presumed interacting regions highlighted.

To further clarify the structural components and the likely interacting surfaces of the complex, and
2.4. Molecular
Dynamics
Simulations on
vCCI:vMIP-II
to gain insight
into the
extraordinarily
tight
binding between vCCI/35K and vMIP-II, we carried out
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interacting
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molecular dynamics
create 1 microsecond
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trajectories
of both
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insight into the extraordinarily
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binding between
vCCI/35K
wevCCI:MIP-1β
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complexand
and
the vCCI:vMIP-II
complex. Both
are based
onand
thevMIP-II,
reported
out(Protein
molecular
dynamics
(MD) simulations
create
1 microsecond
(μs) trajectories
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structure
Data
Bank (PDB)
ID: 2FFK),tobut
for MIP-1β,
the residues
were changed
to reflect
vCCI:MIP-1β complex and the vCCI:vMIP-II complex. Both trajectories are based on the reported
the wild type chemokine, as opposed to the triple mutant used in that structure determination [13].
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for the final 500 nanoseconds of the simulation, for a total of 51 structures analyzed per complex.
The three complexes show different total amounts of buried surface area, as shown in Table 2.
Additionally, specific residue–residue contacts vary between the three different complexes. Figure S5
shows interactions of residues that are occluded during the simulation upon complex formation at
least 50% of the time, and that are within 2.8 Å of the partner residue in at least 50% of the structures
sampled every 20 ns for the final 500 ns of the trajectory.
Table 2. Buried surface area between vCCI and chemokine variants averaged over 51 structures
analyzed during the final 500 ns of simulation.
Complex

vCCI Buried Surface Area (Å2 )

Chemokine Buried Surface Area (Å2 )

vCCI:vMIP-II

1473

1528

vCCI:MIP-1β wild type

1355

1392

vCCI:MIP-1β K45A/R46A/K48A
(variant used in 2FFK structure
determination)

1020

1060

A comparison of the dynamics trajectories of vCCI/35K binding to vMIP-II and to MIP-1β shows
some striking differences, in particular, revealing several possible interactions that may account for the
approximately 10-fold tighter binding for vMIP-II to vCCI/35K. First, at the end of the simulation, the
total buried surface area for vMIP-II in complex is 1528 Å2 , while the buried surface area for MIP-1β in
complex is 1392 Å2 . Second, as shown in Figures 5 and 4C, during the time course of the trajectory,
vCCI/35K shows an overall larger number of hydrogen bonds with vMIP-II than with MIP-1β. Third,
the flexible, negatively charged loop in the 52–77 region of vCCI (between beta strands 2 and 3)
makes more contact, including a larger number of hydrogen bonds over the course of the trajectory,
with vMIP-II than with MIP-1β. And finally, during the 1 µs trajectory, vMIP-II shows overall more
interactions with vCCI than does MIP-1β, in particular, at the N-terminus of the chemokine where a
large portion of that region of vMIP-II lays across the vCCI binding face, while the MIP-1β N-terminus
does not.
The vCCI:vMIP-II trajectory shows several individual interactions that illuminate aspects of
their binding and complementary interactions, including significant contact throughout the trajectory
between residues E143 on vCCI/35K and residue R18 in vMIP-II (Figure 6A); and interaction between
the negatively charged loop between strands β2 and β3 in vCCI/35K with K45/R46 in vMIP-II
(Figure 6C). A similar trajectory is seen for vCCI:MIP-1β, with MIP-1β residue R18 showing interactions
with E143, as well as D141 of vCCI (Figure 6B). However, vMIP-II’s R18 residue also shows interaction
with vCCI residue D75 for almost half the time steps in the trajectory, while no such interaction is
observed with MIP-1β. The trajectories also show both vMIP-II and MIP-1β have their 24/45/46
position residues clustered together, and interacting with the vCCI loop between β2 and β3, but
the interaction is much more extensive in the vCCI:vMIP-II complex (Figure 6C,D and Figure 4C).
The N-terminus of each of the chemokines also behaves very differently in the trajectory. vMIP-II
shows considerably more interaction with vCCI throughout its N-terminus for much of the trajectory,
while the MIP-1β trajectory shows an N-terminus that does not appear to interact consistently with
vCCI, with main contacts to the binding partner not starting until residue 8. In total, the simulation
results point to possible reasons why vCCI shows different binding constants to various partners.
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more tightly than most other chemokines [10]. Others have used a scintillation proximity assay [35]
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including early qualitative work that suggested that vCCI/35K bound vMIP-II more tightly than most
other chemokines [10]. Others have used a scintillation proximity assay [35] and surface plasmon
resonance [14,16,17] to show that vCCI/35K binds a variety of chemokines at levels ranging from
sub-nanomolar to 20 nM.
Analysis of chemical shift perturbation by NMR indicates that vCCI/35K interacts with vMIP-II
using residues similar to those that have been shown to be important in binding by vCCI to other
chemokines, MIP-1β/CCL4, and eotaxin-1/CCL11 [11,13], such as acidic residues in the 141/143
area. Similarly, chemical shift perturbation of vMIP-II upon binding vCCI/35K shows chemical shift
changes in generally known areas, including the region near R18, as well as the area near the so-called
N-loop of the chemokine, where hydrophobic L13 is located (Figure 3). While NMR chemical shift
perturbation is a powerful tool, there are two main drawbacks. First, while a perturbation suggests
a locus for protein–protein interaction, and one can infer regions of interaction between proteins,
it does not confirm a pairwise interaction with the binding partner. Second, 2D 15 N HSQC spectra
can be ambiguous in terms of assigning peaks upon movement. To resolve ambiguity would require
13 C-labeling of the protein(s) and a series of 3D NMR experiments [11]. Therefore, we chose to
pursue molecular dynamics simulations, which provide a high resolution “movie” (within certain
approximations) of the structure and motions of all atoms in the protein and surrounding solvent,
and can delineate specific interactions and provide insight into differences in affinity.
Atomistic classical molecular dynamics (MD) is a well-established tool for studying protein
structure and dynamics [36]. In typical protein MD, the motions of all atoms are simulated using
empirical force fields that approximate the forces due to bonded and non-bonded interactions.
The resulting output is a high-resolution series of atomic motions that can be analyzed to characterize
the structure and dynamics of the protein, and infer the energy causes of the observed behavior.
With modern computers and MD software, it is feasible to routinely run simulations of moderately
large proteins (including a solvation shell of water and ions) for microsecond timescales, with the
largest published MD simulations reaching millisecond times [37]. The accuracy is limited by the
approximate nature of the force field and the limitation that bonds are not broken or formed during the
simulations (including protonation and deprotonation of acid and base sites), but MD has been shown
able to accurately predict protein properties, such as the folded conformation of small proteins [38].
In the investigation of the vCCI:vMIP-II complex, a 1 µs MD trajectory was run, providing great
insight into likely interactions that were not observable and/or confirmable by our NMR experiments
to this point. In general, the hypothesis that these two viral proteins may be a near-ideal binding pair
is supported by the MD trajectories, which show that that vCCI:vMIP-II complex has a larger buried
surface area (including the vMIP-II’s N-terminus) and a greater number of hydrogen bonds throughout
the trajectory, including more interactions between the chemokine and the negatively charged flexible
loop of vCCI than the vCCI:MIP-1β complex. The MD simulations also provide context for specific
regions of interaction that may be useful in general for a vCCI:chemokine complex. For example,
D141 and E143 in vCCI were observed to contact R18 in the vCCI:MIP-1β structure [13], and this
R18 was found to be critical for vCCI/35K binding in other chemokines [11,13,16,17]. However,
mutational studies on vCCI/35K showed E143 to be more important than D141 [15]. The MD trajectory
provides an explanation, showing significant, continuous interaction between E143 (vCCI/35K) and
R18 (vMIP-II), while almost no close interaction across the trajectory is observed with D141. In the
vCCI:MIP-1β trajectory, significant hydrogen bonding interaction (although below the 50% threshold
for Figure 4C) is observed between R18 of the chemokine and both E143 and D141 of vCCI, although
the interaction with E143 predominates.
The MD trajectory also provides a possible explanation for other unexplained mutational results.
In the original structure of the complex between vCCI/35K and MIP-1β /CCL4, it was observed
that both Y80 and R89 in vCCI/35K appeared close in space to the 48th position of MIP-1β [13].
In many chemokines, this position contains a large, basic residue that could be expected to both
sterically and electrostatically clash with those groups. It had been noted that mutation of this
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residue to the smaller Ala48 increased affinity for a similar chemokine MCP-1/CCL2 [16,17]. Indeed,
MIP-1β was mutated from a Lys to an Ala at that position in the structure, and that mutation was
Int. J. Mol. Sci.
18, 1778
of 18
attributed
to2017,
tighter
binding to vCCI. In an attempt to design a vCCI/35K that was better able to11bind
chemokines, White et al. mutated each Y80 and R89 to Ala in vaccinia vCCI/35K, hypothesizing that
these positions
would
better
interact
with better
the large
basicwith
residue
of a basic
chemokine
[15].
aresidue
smaller,inuncharged
residue
in these
positions
would
interact
the large
residue
of
Interestingly,
while
the
vCCI/35K
R89A
mutation
did
lead
to
a
better
chemokine
binding
ability,
a chemokine [15]. Interestingly, while the vCCI/35K R89A mutation did lead to a better chemokine
Y80A completely
abolished
the activity
of the
protein.of
The
trajectory
of Y80
in the vCCI:MIP-1β
binding
ability, Y80A
completely
abolished
the activity
theMD
protein.
The MD
trajectory
of Y80 in the
complex
shows
the
tyrosine
side
chain
of
vCCI
consistently
forming
a
hydrogen
bond
with
the
vCCI:MIP-1β complex shows the tyrosine side chain of vCCI consistently forming a hydrogen
bond
backbone
nitrogennitrogen
of Lys48
of MIP-1β
(Figure
4C and
7B).7B).
This
Y80
not
with
the backbone
of Lys48
of MIP-1β
(Figures
4C and
This
Y80hydrogen
hydrogenbond
bond was
was not
consistently
observed
in
the
vCCI:vMIP-II
trajectory,
although
the
trajectory
shows
consistent
contact
consistently observed in the vCCI:vMIP-II trajectory, although the trajectory shows consistent contact
between these
these residues
residues (Figure
(Figure S5).
S5). In
In either
either case,
case, the
the Y80
Y80 in
in this
this crowded
crowded area
area of
of the
the protein
proteinshows
shows
between
little
motion
and
appears
to
be
holding
open
the
negatively
charged
loop
in
vCCI.
The
Y80
residue
little motion and appears to be holding open the negatively charged loop in vCCI. The Y80 residue in
in vCCI
been
mutated
by Arnold
et who
al., who
replaced
tyrosine
arginine.
mutation
vCCI
hashas
alsoalso
been
mutated
by Arnold
et al.,
replaced
tyrosine
withwith
arginine.
ThisThis
mutation
did
did
also
lead
to
loss
of
chemokine
binding
ability,
although
in
this
case,
the
cause
is
likely
placing
also lead to loss of chemokine binding ability, although in this case, the cause is likely placing a basica
basic
on near
vCCIthe
near
the Arg48
of a chemokine
Arg
onArg
vCCI
Arg48
of a chemokine
[14]. [14].

Figure
Figure 7.7. Interactions illuminated by molecular
molecular dynamics
dynamics simulation
simulation of
of the
the vCCI:MIP-1β
vCCI:MIP-1β and
and
vCCI:vMIP-II
vCCIisisininred
redribbon
ribboninin
both
instances,
bound
vMIP-II
in blue
ribbon,
vCCI:vMIP-II complex.
complex. vCCI
both
instances,
bound
vMIP-II
is inisblue
ribbon,
and
and
bound
MIP-1β
in green
ribbon.
Interaction
betweenI184
I184ofofvCCI
vCCI(orange)
(orange) and
and I41
I41 of
bound
MIP-1β
is inis green
ribbon.
(A)(A)
Interaction
between
of vMIP-II
vMIP-II
(cyan),
vMIP-II
(yellow).
C12
ofof
vMIP-II
(cyan),as
aswell
wellas
asS182
S182ofofvCCI
vCCI(orange)
(orange)with
withthe
thebackbone
backboneofofC51
C51ofof
vMIP-II
(yellow).
C12
vMIPisII also
indicated
in
yellow;
(B)
Interaction
between
Y80
of
vCCI
(orange)
and
the
backbone
of
of
is also indicated in yellow; (B) Interaction between Y80 of vCCI (orange) and the backbone K48
of K48
MIP-1β
(green).
of MIP-1β (green).

TheMD
MDtrajectory
trajectory
helped
reveal
several
interesting
interactions
that
NMR
had
The
hashas
helped
reveal
several
interesting
interactions
that NMR
alone
hadalone
difficulty
difficulty explaining.
Arnold
et al.that
observed
that the
of residues
and
(using
the
explaining.
Arnold et al.
observed
the mutation
of mutation
residues S182
and I184S182
(using
theI184
present
vCCI
present vCCI
numbering)
resulted
in of
substantial
loss ofespecially
binding activity,
especially
for I184
[14].
numbering)
resulted
in substantial
loss
binding activity,
for I184 [14].
However,
previous
However,shift
previous
chemical
assignments
vCCI with[11,13]
other as
chemokines
as work
well as
the
chemical
assignments
forshift
vCCI
with other for
chemokines
well as the[11,13]
current
with
current are
work
withtovMIP-II,
quantify
theinshifts
these
vCCI. The
MD
vMIP-II,
unable
quantifyare
the unable
shifts totothese
residues
vCCI.toThe
MDresidues
trajectory,inhowever,
reveals
trajectory,
however,
reveals
an
interaction
between
VCCI
I184
and
vMIP-II
Ile41
and
Cys51,
an interaction between VCCI I184 and vMIP-II Ile41 and Cys51, seemingly to help anchor vCCI to
seemingly
to throughout
help anchorthe
vCCI
to the(Figure
chemokine
throughout
trajectory
7A); this
the
chemokine
trajectory
7A); this
interactionthe
is also
seen in (Figure
the vCCI:MIP-1β
interactionexplaining
is also seen
in chemical
the vCCI:MIP-1β
trajectory,
explaining
chemical
shift
changes
in
trajectory,
large
shift changes
in chemokines
in large
the region
39–42.
vCCI
Ser182,
chemokines
in
the
region
39–42.
vCCI
Ser182,
meanwhile,
appears
to
have
formed
a
hydrogen
bond
meanwhile, appears to have formed a hydrogen bond to the backbone N-H of C51 in both vMIP-II and
to the backbone
of C51
bothchemical
vMIP-IIshift
and changes
MIP-1β.to
This
explain
large chemical
MIP-1β.
This mayN-H
explain
thein
large
thatmay
region
of thethe
spectra.
This was shift
also
changes to
region of shift
the spectra.
was also
in the chemical
observed
inthat
the chemical
changesThis
of eotaxin
in observed
the vCCI:eotaxin
complexshift
[11].changes of eotaxin
in the
vCCI:eotaxin
complexof[11].
Overall,
a combination
biochemical, biophysical, and computational experiments have been
a combination
of biochemical,
biophysical,
experiments
been
used Overall,
to provide
a comprehensive
explanation
of the basisand
forcomputational
the high affinity
interactionhave
between
used
to
provide
a
comprehensive
explanation
of
the
basis
for
the
high
affinity
interaction
between
vCCI/35K and vMIP-II. These proteins each exemplify a highly evolved mechanism to mimic and/or
vCCI/35K and vMIP-II. These proteins each exemplify a highly evolved mechanism to mimic and/or
subvert the mammalian immune system, and an understanding of their interaction will be useful in
both their development as possible therapeutics and in general protein design for
immunomodulation.
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subvert the mammalian immune system, and an understanding of their interaction will be useful in
both their development as possible therapeutics and in general protein design for immunomodulation.
4. Materials and Methods
4.1. Protein Purification
4.1.1. Purifying vCCI from E. coli
The gene sequence encoding the rabbit pox vCCI was slightly modified by PCR to allow for proper
cleavage by enterokinase, which does not cut efficiently near proline. DNA coding for Met-Pro in the
first two amino acids was replaced with DNA coding for Ala-Met-Ala. The resulting gene was cloned
into the pET32a vector utilizing the restriction sites NcoI and HindIII. The plasmid was transformed
into E. coli BL21 (DE3) (Novagen, Madison, WI, USA) competent cells and expressed in Luria broth or
minimal media with 15 NH4 Cl as the sole nitrogen source. Protein production was induced when the
absorbance at 600 nm reached 0.70–0.75 with the addition of isopropyl β-D-1-thiogalactopyranoside
(IPTG) to 1mM and incubated with shaking at 22 ◦ C for 20 h. The cells were then harvested by
centrifugation at 4200× g, 4 ◦ C for 12 min and supernatant was discarded.
The cell pellet was resuspended in 6 M guanidine hydrochloride, 200 mM NaCl, and 50 mM Tris
(pH 8.0) and was lysed by three passages through a French press and then centrifuged at 27,000× g for
1 h. The supernatant was decanted and 15 mM β-mercaptoethanol (β-ME) was added and allowed to
stir at room temperature for 2 hours to reduce. The solution was then loaded onto a nickel chelating
column (Qiagen, Hilden, Germany) equilibrated with the resuspension buffer containing 15 mM βME
after a thorough 0.3 M imidazole wash to remove unbound nickel. The column containing the bound
vCCI was washed with 10 column volumes of resuspension buffer containing 15 mM βME, and then
with 10 column volumes of wash buffer (6 M Guanidinium chloride, 200 mM NaCl, 15 mM βME,
80 mM NaOP, pH 7.2). Proteins were eluted from the column using 6 M guanidine hydrochloride,
200 mM NaCl, and 60 mM NaOAc, pH 4. Fractions containing the eluted protein were identified by
absorbance at 280 nm and then pooled together. βME was then added to a concentration of 25 mM.
The fractions were allowed to stir for one hour at room temperature, followed by stirring for 12 hours
at 4 ◦ C overnight.
The protein was then refolded by dropwise addition to 20x volume of ice-cold refolding buffer
(9.6 mM NaCl, 0.4 mM KCl, 2 mM CaCl2 , 2 mM MgCl2 , 550 mM L-arginine hydrochloride, 400 mM
sucrose, 3 mM reduced glutathione (GSH), 0.3 mM oxidized glutathione (GSSG), 50 mM Tris, pH 8),
and then allowed to stir 24 h at 4 ◦ C. The solution was dialyzed 4 times into 4 liters 200 mM NaCl,
2 mM CaCl2 , 20 mM Tris, pH 7.4 buffer at 4 ◦ C.
To cleave the thioredoxin fusion tag from the purified protein, the samples were incubated for
12 hours at 4 ◦ C with 650 nM of the protease enterokinase. The samples were then dialyzed 4 times
into 4 L of 20 mM Bis-Tris, 50 mM NaCl pH 7.1 and then passed through a 0.2 µm nylon filter to then be
purified on a HiTrap™ Q HP Column (GE Healthcare Life Sciences, Chicago, IL, USA) using a gradient
from 50 mM NaCl, 20 mM Bis-Tris pH 7.1 to 1 M NaCl, 20 mM Bis-Tris pH 7.1, to separate the cleaved
tag from vCCI. The fractions were analyzed on an SDS-PAGE gel to confirm purity and then fractions
containing vCCI were concentrated using the Amicon concentrators (Millipore, Billerica, MA, USA),
and buffer was changed to 100 mM NaCl, 20 mM NaOP pH 7.0 with 0.02% NaN3 for NMR studies.
4.1.2. Expression and Purification of vMIP-II
The gene for vMIP-II was placed into a pET28 vector and transformed into Escherichia coli BL21
(DE3) (Novagen, Madison, WI, USA) competent cells and expressed in either minimal media with
15 NH Cl as the sole nitrogen source for 15 N-labeled samples or Luria Broth for 14 N-labeled samples.
4
Protein production was induced by adding IPTG to 1 mM and incubated with shaking at 37 ◦ C for 5 h.
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The cell pellet was resuspended in 6 M guanidine hydrochloride, 200 mM NaCl, 10 mM
benzamidine, 50 mM Tris (pH 8.0) and were lysed by French press and then centrifuged at 27,000× g
for 1 h. The soluble portion was then loaded onto a nickel chelating column (Qiagen, Hilden, Germany)
equilibrated with the resuspension buffer. Proteins were eluted from the column using a pH gradient
with 6 M guanidine hydrochloride, 200 mM NaCl, 60 mM NaOAc (pH 4) followed by addition of
10 mM βME while stirring for 2 hours at room temperature. The proteins were then refolded by
dropwise addition into 10× volume of refolding buffer (550 mM L-arginine hydrochloride, 200 mM
NaCl, 1 mM EDTA (Ethylenediaminetetraacetic acid), 1 mM reduced glutathione (GSH), 0.1 mM
oxidized glutathione (GSSG), 50 mM Tris, pH 8), and then allowed to stir overnight at 4 ◦ C. The solution
was dialyzed three times into 4 L of 200 mM NaCl, 20 mM Tris pH 8 buffer at 4 ◦ C.
To cleave the Small Ubiquitin-like Modifier (SUMO) fusion tag from the purified protein,
the samples were incubated for 12 hours with 100 nM of the Ubl-specific protease 1 (ULP-1). The protein
solution was then centrifuged to remove precipitated material and added onto a second nickel chelating
column (Qiagen, Hilden, Germany), with flow-through containing the cleaved vMIP-II being collected.
The samples were then dialyzed and purified on a C4 reversed-phase chromatography column (Vydac,
Hesperia, CA, USA), using an acetonitrile gradient. The fractions were analyzed on an sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel to confirm purity and lyophilized in a
Labconco freeze-dry system.
The proteases used in these purifications were produced and purified in our laboratory as briefly
described: ULP1 or enterokinase protease were proteins were expressed in LB medium using a pET-28b
vector and the cells were collected and French pressed. The ULP1 protease from the supernatant
was purified using a nickel chelating column [39]. The enterokinase was found in the inclusion
body and resuspended in 6M guanidinium buffer before being purified using a nickel chelating
column. Enterokinase was then dialyzed in buffer to allow for refolding and tested for activity through
self-cleavage of the fusion tag (manuscript in preparation).
Proteins used in fluorescence anisotropy studies were purified as specified in [11]. vCCI for these
experiments were made using a gene encoding rabbitpox virus vCCI cloned into pPIC9K plasmid and
then transformed into Pichia pastoris strain SMD1168 (Invitrogen, Carlsbad, CA, USA) and purified as
previously described [13].
4.2. Nuclear Magnetic Resonance (NMR) Spectroscopy
All NMR samples were made in 20 mM sodium phosphate buffer, 100 mM NaCl with 10% D2 O,
5 µM 2,2-dimethyl-2-silapentane-5-sulfonic acid (DSS), and 0.02% NaN3 , with a final pH of 7.0. 15 N
labeled lyophilized vMIP-II was resuspended into 5 mM NaOP buffer, pH 2.8 in order to dissolve the
protein, and then 10 µL was added to 340 µL NMR buffer (either alone or with 150 uM 14 N-vCCI) for
final vMIP-II concentration of 50-60 µM. 14 N-vMIP-II was also resuspended into 5 mM NaOP, pH 2.8,
and 10 µL was added to 340 µL NMR buffer containing 15 N-labeled vCCI, for a final concentration
of 150 µM VMIP-II in the sample. vCCI was exchanged into NMR buffer as explained in the above
sections, with final concentrations for 15 N samples being 50–60 µM.
All HSQC NMR data were acquired on a four-channel 600 MHz Bruker Avance III spectrometer
(Bruker Corp, Billerica, MA) equipped with a (GRASP II) gradient accessory and a (TCI) cryoprobe
with an actively shielded Z-gradient coil. Spectra with 15 N-labeled vMIP-II were measured at 25 ◦ C;
spectra with 15 N-labeled vCCI were measured at 37 ◦ C. The chemical shift was referenced relative
to internal DSS [40]. The data were processed using NMRPipe [41] and analyzed using PIPP [42]
(Available online: https://spin.niddk.nih.gov/bax/software/NMRPipe/). For HSQC spectra, sweep
width = 8474.576(1 H) and 1766.784 Hz (15 N), with 1280 points in 1 H and 128* (256 total) points in 15 N.
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The weighted average chemical shift change of the 1 H and 15 N resonances for each residue upon
binding was calculated using the equation [43]:

∆δobs =

v
u

2
u
∆δ
2
t ∆δ H + 5N
2

(1)

where ∆δH and ∆δN are the chemical shift changes of the 1 H and 15 N dimensions, respectively. Here,
the ∆δobs is the difference between bound and free form of 15 N-labeled complexes. Due to lack of
13 C labeling, some bound peak identifications were estimates; to be conservative, the nearest residue
without a clear origin were assumed to belong to the residues in question.
4.3. Isothermal Titration Calorimetry (ITC)
A Nano ITC Low Volume isothermal titration calorimeter (TA Instruments, New Castle, DE, USA)
was loaded with degassed 10 uM vCCI in 20 mM NaOP, 100 mM NaCl, pH 7.0 and water in the reference
cell. Twenty 2.5 µL injections of 100 µM vMIP-II also in 20 mM NaOP, 100 mM NaCl, pH 7.0 were then
injected at 300 second intervals, with a 350 rpm stirring speed. Baseline selection, buffer-into-buffer
blank was subtracted from the data, and peak-by-peak manual integration was performed using
NanoAnalyze software (TA Instruments, New Castle, DE, USA). The data for an independent binding
site model was provided by the software. The Kd was below detectable limits (10−10 nM).
4.4. Fluorescence Anisotropy
Fluorescence anisotropy experiments were carried out in three independent experiments as
described in [11], at 25 ◦ C and pH of 7.0 utilizing a Photon Counting (PC1) spectrofluorimeter and
VINCI software (ISS, Champaign, IL, USA), with an excitation wavelength of 497 nm and emission
wavelength of 524 nm. The obtained data were then fit to a system of mass conservation equations as
well as the following equation:
[ L] f ree × Ka
(2)
θ=
1 + [ L] f ree × Ka
where θ is the fraction of bound eotaxin-K63C, [L]free is the concentration of unbound vCCI, and Ka is
the association constant for the complex.
For the competitive binding experiment, a 1:1 ratio of the vCCI:eotaxin-K63C (both proteins were
prepared and purified as described in [11], with eotaxin-K63C labeled with fluorescein-5-maleimide)
complex was prepared at a concentration of 8 nM. 500 µL of this complex was then mixed with
varying amounts of unlabeled vMIP-II and incubated 30 minutes at 25 ◦ C. Anisotropy measurements
were taken and the values were normalized so that 1 represents the 100% bound state. The resulting
data were fit using Scientist software (Micromath, Salt Lake City, UT, USA) to a system of equations
described previously [44,45].
4.5. Molecular Dynamics
All-atom molecular dynamics was performed on three vCCI:MIP complexes. All three complex
structures were based on the NMR structure of the VCCI:MIP-1β complex (PDB: 2FFK), which has
three mutations from the wild type MIP-1β sequence. We recreated the original wild type structure by
in silico editing of the 2FFK experimental structure. The vCCI:vMIP-II starting structure was created
from the vCCI:MIP-1β structure by computationally superimposing the experimental vMIP structure
(PDB code 1VMP) on the MIP-1β chain, to minimize the average difference between the corresponding
Cα backbone atoms (see Figure S2). The net charge (−11 vCCI:vMIP-II, −26 vCCI:MIP-1β mutant,
−23 vCCI:MIP-1β wild type) on the complexes was neutralized by adding Na+ ions and additional
Na+ /Cl− pairs (~60) were added to yield an ion concentration of approximately 70 millimolar. After
short equilibration runs, a full 1 microsecond of MD simulation was run using Gromacs 5.0.7 [46–48]
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using the NPT ensemble, the Verlet cutoff scheme and a 2 fs timestep. All bonds to hydrogen were
constrained to their equilibrium length using the LINCS algorithm [49]. Temperature was maintained
at 300K using the Bussi et al. thermostat [50] and pressure at 1 bar using the Parrinello-Rahman
barostat [51]. The simulations were performed using the AMBER99SB-ILDN force field for the
protein [52] and the TIP3P water model [53].
4.6. Figure Preparation
All structure figures were prepared by using UCSF Chimera (UCSF Resource for Biocomputing,
Visualization, and Informatics, San Francisco, CA, USA) [28].
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/8/1778/s1.
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Abbreviations
vCCI
vMIP-II
E. coli
NMR
HSQC
NaOP
HHV-8
MIP-1β
CCL4
IPTG
DSS
β-ME
RMSD
RMSF
MD

Viral CC Chemokine Inhibitor; also called 35K or vCCI/35K
Viral macrophage inflammatory protein II
Escherichia coli
Nuclear magnetic resonance
Heteronuclear single quantum coherence
Sodium phosphate
Human herpesvirus 8, Kaposi’s sarcoma-associated herpesvirus
Macrophage inflammatory protein β, also known as CCL4
CC chemokine ligand 4, also known as MIP-1β
Isopropyl β-D-1-thiogalactopyranoside
4,4-dimethyl-4-silapentane-1-sulfonic acid
β-mercaptoethanol
Root mean squared deviation
Root mean squared fluctuation (for specific residues)
Molecular dynamics
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